
Liang Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4103292/publications.pdf Version: 2024-02-01



LIANCLU

#	Article	IF	CITATIONS
1	Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. Cancer Cell, 2014, 25, 501-515.	16.8	1,198
2	Breast-cancer-secreted miR-122 reprograms glucoseÂmetabolism in premetastatic niche toÂpromoteÂmetastasis. Nature Cell Biology, 2015, 17, 183-194.	10.3	895
3	Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nature Cell Biology, 2018, 20, 597-609.	10.3	306
4	Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. Scientific Reports, 2014, 4, 5750.	3.3	270
5	Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting <i>ONECUT2</i> . Cancer Research, 2019, 79, 3608-3621.	0.9	129
6	Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. Frontiers in Immunology, 2017, 8, 404.	4.8	73
7	TGFβ Induces "BRCAness―and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes. Molecular Cancer Research, 2014, 12, 1597-1609.	3.4	56
8	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death and Differentiation, 2018, 25, 1160-1173.	11.2	51
9	The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study. Frontiers in Immunology, 2021, 12, 772450.	4.8	42
10	Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clinical Cancer Research, 2018, 24, 2370-2382.	7.0	39
11	Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial	1.7	25
12	(Keystone-001). Annals of Translational Medicine, 2022, 10, 229-229. Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). Frontiers in Oncology, 2022, 12, 831345.	2.8	18
13	CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell Death and Disease, 2022, 13, 441.	6.3	18
14	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death and Disease, 2019, 10, 475.	6.3	16
15	Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway. Molecular Immunology, 2017, 81, 102-107.	2.2	11
16	Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. Signal Transduction and Targeted Therapy, 2020, 5, 244.	17.1	10
17	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. Frontiers in Immunology, 2021, 12, 779248.	4.8	3
18	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer Biology and Medicine, 2021, 18, 0-0.	3.0	2